Mereo BioPharma Group faces securities fraud investigation.

Pomerantz LLP is investigating claims of securities fraud against Mereo BioPharma Group plc on behalf of investors. The investigation concerns whether the company and its officers or directors have engaged in unlawful practices. The investigation was prompted by a press release from Mereo and its development partner Ultragenyx Pharmaceutical Inc. regarding the progress of the Orbit study evaluating UX143 for osteogenesis imperfecta.

NEW YORK, July 02, 2025 — Pomerantz LLP, a leading firm in corporate, securities, and antitrust class litigation, has initiated an investigation into claims on behalf of investors of Mereo BioPharma Group plc (NASDAQ: MREO). The investigation focuses on whether the company and its officers or directors have engaged in securities fraud or other unlawful business practices [1].

The investigation was prompted by a press release issued by Mereo and its development partner Ultragenyx Pharmaceutical Inc. on July 9, 2025. The announcement stated that the randomized, placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) is progressing toward a final analysis, expected around the end of the year [2]. Following this news, Mereo's American Depositary Receipt (ADR) price fell by $1.25 per share, or 42.52%, to close at $1.69 per share on July 10, 2025 [2].

Investors are advised to contact Danielle Peyton at Pomerantz LLP for more information or to join the class action. The contact details are 646-581-9980, ext. 7980 [1, 2, 3].

Mereo BioPharma Group plc is a biopharmaceutical company that develops medicines for rare diseases and cancer. The company is working on treatments like setrusumab for brittle bone disease and alvelestat for severe lung disease [4]. Despite the potential of the company's pipeline, recent market reactions suggest investor concerns about the company's practices and the progress of its clinical trials.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, London, and Paris, has a long history of recovering multimillion-dollar damages awards on behalf of class members. The firm is known for its expertise in securities class actions and has recovered numerous damages awards in the past [1, 2].

References:

[1] https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-mereo-biopharma-group-plc---mreo-302521606.html
[2] https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-mereo-biopharma-group-plc---mreo-302525782.html
[3] https://www.bakersfield.com/ap/news/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-mereo/article_147bd3c8-62b9-5682-88e8-6c9e475da3aa.html
[4] https://finance.yahoo.com/news/mereo-biopharma-group-mreo-announced-134505525.html